Recent

% | $
Quotes you view appear here for quick access.

Rigel Pharmaceuticals, Inc. Message Board

  • delphioracle2009 delphioracle2009 Jun 23, 2013 6:01 PM Flag

    Big Boys of Biotech investing seems to ber moving into RIGL ... May reach $7 within a weeks ...

    Compared to EXAS & VVUS by cash, debt & EPS of 2013 & 2014, RIGL is worth over $10/share
    Comparing RIGL balance sheet to that of upcoming biotech companies EXAS & VVUS ... and comparing their projected earnings growth and which all institutions are holding RIGL, VVUS & EXAS ... RIGL looks like a high yield DIAMOND MINE ...

    EXAS & VVUS have just one product in the pipeline, EXAS just have $1.66/share in cash [$108.12M cash - $2.04M debt over 64.03M shares] and are expected to make a loss of $1.27/share for 2013 & 2014, leaving them only less thatn $0.40/share in cash by end of 2014 ... VVUS that is expected to make a loss of about $1.66/share in 2013 and about $0.74/share in 2014 making a total loss of $3.40/share and has only $2.13/share ..

    EXAS & VVUS have just one product in the pipeline, EXAS just have $1.66/share in cash [$108.12M cash - $2.04M debt over 64.03M shares] and are expected to make a loss of $1.27/share for 2013 & 2014, leaving them only less thatn $0.40/share in cash by end of 2014 ... VVUS that is expected to make a loss of about $1.66/share in 2013 and about $0.74/share in 2014 making a total loss of $3.40/share and has only $2.13/share ..

    On the other hand RIGL is now expected to make a loss of $1.17 for 2013 & $0.90 for 2014 adding to a total of $2.07/share till end of 2014 and they have $3.13/share in cash and no debt ...

 
RIGL
2.51-0.18(-6.69%)Feb 5 4:00 PMEST